Business
Vor Bio Announces $175 Million Private Placement
CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it has entered into a securities purchase agreement for a private placement in public equity financing (the “PIPE”) that is expected to result in gross proceeds of approximately $175 million, before deducting expenses. Private Placement Pursuant to the terms of the securities purchase agreement, at the closing of
About this update from Vor Biopharma Inc.
[{"type":"image","alt":"Vor Biopharma","displaySize":"","headline":null,"caption":"Vor Biopharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/06662e47289d17345678186e391880ec"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/B2LYyFLcnDdgjzJKo4HDhA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/06662e47289d17345678186e391880ec","width":300,"height":108}},"lazy":false},{"type":"text","content":"CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it has entered into a securities purchase agreement for a private placement in public equity financing (the “PIPE”) that is expected to result in gross proceeds of approximately $175 million, before deducting expenses.","length":404,"tagName":"p"},{"type":"text","content":"Private Placement","length":17,"tagName":"p"},{"type":"text","content":"Pursuant to the terms of the securities purchase agreement, at the closing of the PIPE, Vor Bio will issue prefunded warrants (the “Warrants”) to purchase an aggregate of 700,000,000 shares of common stock at a purchase price of $0.25 per Warrant.","length":247,"tagName":"p"},{"type":"text","content":"The PIPE included a syndicate of world-class investors including Vor Bio’s existing stockholder RA Capital Management, as well as Mingxin Capital, Forbion, Venrock Healthcare Capital Partners, Caligan Partners and NEXTBio.","length":222,"tagName":"p"},{"type":"text","content":"Vor Bio intends to use the net proceeds from the PIPE to advance development of its clinical pipeline and for general corporate purposes. The PIPE is expected to close on June 27, 2025, subject to the satisfaction of customary closing conditions.","length":246,"tagName":"p"},{"type":"text","content":"The Warrants have an exercise price of $0.0001 per share and will become exercisable upon approval by Vor Bio stockholders of the issuance of the shares underlying the Warrants. Vor Bio intends to hold a special stockholder meeting to approve, among other things, the issuance of the underlying shares.","length":302,"tagName":"p"},{"type":"text","content":"The securities being issued and sold in the PIPE have not been registered under...